A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT03313960

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03313960
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03313960. Randomized; no masking; primary purpose treatment. Start 2017-10-05 (actual); primary completion 2018-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Afrezza plus One Drop | Premium
Intervention (Other)
One Drop | Premium
Lead sponsor
Informed Data Systems, Inc. (class: industry)
Collaborator
Mannkind Corporation (class: industry)

Record details

Record id
cardio:ct-nct03313960
Content hash
97ca892720530c6fd02df09f6bc9efdedb161c6f633984a1ab4c9f5d6cbb71b4